What is it about?
This is a brief perspective piece that summarizes the key clinical information, the cost-effectiveness analysis, and the policy implications of the research.
Featured Image
Why is it important?
Patisiran and inotersen are new drugs for a condition that previously have very few effective options. However, high drug prices associated with these drugs prompt questions about cost-effectiveness.
Perspectives
This perspective piece provides a brief summary of a full ICER report and a full day public meeting. One can read the full report and view the webcast of the meeting, but this paper provides a quick summary of all the key elements.
William Dreitlein
Institute for Clinical and Economic Review
Read the Original
This page is a summary of: The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis, Journal of Managed Care & Specialty Pharmacy, January 2019, Academy of Managed Care Pharmacy,
DOI: 10.18553/jmcp.2019.25.1.010.
You can read the full text:
Contributors
The following have contributed to this page
